AAVantgarde was co-founded by Professor Alberto Auricchio and originated from the research activities carried out at Tigem (Telethon Institute of Genetics and Medicine) in Naples, Italy, and supported by Sofinnova Partners who participated in a seed round in June 2021.  This was followed in June 2023 by a €61 Million Series A Financing co led by Atlas Venture and Forbion, with participation from the Company’s founding investors, Sofinnova Telethon fund and Longwood Fund.